Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study
Conclusions68Ga-DOTATATE PET/CT and18F-FDG PET/CT are complementary in localizing and discriminating the source of EAS.68Ga-DOTATATE PET/CT combined with18F-FDG PET/CT had higher detection rate than each alone.Trial registration68Ga-DOTATATE PET/CT in Neuroendocrine Tumors (NCT04041882)URL of registryhttps://clinicaltrials.gov/ct2/show/NCT04041882 (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 19, 2021 Category: Nuclear Medicine Source Type: research

Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
ConclusionIn a large sample of 3103 patients at intermediate-high risk of persistent/recurrent disease, 71% of patients achieved a successful ablation. In these intermediate-risk patients, the probability of subsequent recurrence is low and most recurrence occurred in those with already abnormal findings at the first control. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 18, 2021 Category: Nuclear Medicine Source Type: research

Distinguishing nontuberculous mycobacteria from Mycobacterium tuberculosis lung disease from CT images using a deep learning framework
ConclusionThis study shows the efficacy of 3D-ResNet as a rapid auxiliary diagnostic tool for NTB-LD and MTB-LD. Its use can help provide timely and accurate treatment strategies to patients with these diseases. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 16, 2021 Category: Nuclear Medicine Source Type: research

Response to the Letter to the Editor: Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 14, 2021 Category: Nuclear Medicine Source Type: research

Give to Fryback what is Fryback ’s, and to new PET technologies what is new PET technologies’
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 13, 2021 Category: Nuclear Medicine Source Type: research

Correction to: Functional 4-D clustering for characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a prognostic biomarker for breast cancer
A Correction to this paper has been published:https://doi.org/10.1007/s00259-021-05324-0 (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 12, 2021 Category: Nuclear Medicine Source Type: research

Pharmacokinetic studies of [68  Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type
ConclusionEven at low PSA between 0.51 and 0.99  ng/mL, detection rate was 57%. Dynamic imaging showed a time window in the first 10 min where tumour uptake is high, but no bladder activity is measured, aiding accuracy in distinction of local recurrence. Kinetic modelling provided additional information for tumour characterisation by tissue typ e. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 10, 2021 Category: Nuclear Medicine Source Type: research

A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?
Conclusion18F-Fluciclovine PET can identify recurrent disease at low PSA level and PSA rise below accepted Phoenix criteria in patients with suspected BCR after primary radiation therapy, particularly in patients with low PSADT or high PSA velocity. In patients with low PSADT or high PSA velocity, there is an increased probability of extra-pelvic metastases. Therefore, these patients are more likely to benefit from PET/CT or PET/MRI than pelvic MRI alone. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 6, 2021 Category: Nuclear Medicine Source Type: research

Evaluation of P-glycoprotein function at the blood –brain barrier using [18F]MC225-PET
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 5, 2021 Category: Nuclear Medicine Source Type: research

Relationship between amyloid and tau levels and its impact on tau spreading
ConclusionOutside the entorhinal cortex, abnormal levels of cortical tau on PET are rarely found with A β below 40 CL. Above 40 CL prevalence of T+ accelerates in all areas. Moderate Aβ levels are required before abnormal neocortical tau becomes detectable. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 3, 2021 Category: Nuclear Medicine Source Type: research

Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer ’s disease in the context of a structured 5-phase biomarker development framework
ConclusionCurrent literature provides partial evidence for clinical utility of [18F]flortaucipir PET. The aims for phases 1 and 2 were mostly achieved. Phase 3 studies are currently ongoing. Future studies including representative MCI populations and a focus on healthcare outcomes are required to establish full maturity of phases 4 and 5. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 3, 2021 Category: Nuclear Medicine Source Type: research

Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent
ConclusionVR is an appropriate method for assessing early amyloid pathology and that grading theextent of visual amyloid positivity could present clinical value. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 3, 2021 Category: Nuclear Medicine Source Type: research

Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases
ConclusionPreliminary results suggest strong differences in the medial temporal lobe and cortical regions known to be impacted in AD using18F-PI-2620 in patients along the AD trajectory. This work confirms that18F-PI-2620 holds promise as a tool to visualize tau aggregations in AD. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 3, 2021 Category: Nuclear Medicine Source Type: research

Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter
AbstractPurposeRecent research has suggested the use of white matter (WM) reference regions for longitudinal tau-PET imaging. However, tau tracers display affinity for the β-sheet structure formed by myelin, and thus WM lesions might influence tracer retention. Here, we explored whether the tau-sensitive tracer [18F]flortaucipir shows reduced retention in WM hyperintensities (WMH) and how this retention changes over time.MethodsWe included 707 participants from the Alzheimer ’s Disease Neuroimaging Initiative with available [18F]flortaucipir-PET and structural and FLAIR MRI scans. WM segments and WMH were automa...
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 3, 2021 Category: Nuclear Medicine Source Type: research

Differential associations of APOE- ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
AbstractPurposeTo examine associations between theAPOE- ε2 andAPOE- ε4 alleles and core Alzheimer ’s disease (AD) pathological hallmarks as measured by amyloid-β (Aβ) and tau PET in older individuals without dementia.MethodsWe analyzed data from 462 ADNI participants without dementia who underwent A β ([18F]florbetapir or [18F]florbetaben) and tau ([18F]flortaucipir) PET, structural MRI, and cognitive testing. EmployingAPOE- ε3 homozygotes as the reference group, associations betweenAPOE- ε2 andAPOE- ε4 carriership with global A β PET and regional tau PET me...
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 3, 2021 Category: Nuclear Medicine Source Type: research

A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
ConclusionThe temporal meta-ROI can be used for differential diagnosis of dementia patients with [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET with high accuracy, and that using very similar cut-offs of around 1.35 SUVR. This ROI/SUVR cut-off can also be applied across tracers to define tau positivity. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 3, 2021 Category: Nuclear Medicine Source Type: research

New PET technologies – embracing progress and pushing the limits
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 3, 2021 Category: Nuclear Medicine Source Type: research

G. Mariani, S. Vidal-Sicart, R.A. Valdes Olmos (Eds): Atlas of Lymphoscintigraphy and Sentinel Node Mapping, Second Edition
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 3, 2021 Category: Nuclear Medicine Source Type: research

Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
ConclusionPET imaging of the IL-2R, using [18F]FB-IL2, is safe and feasible. In this small patient group, serial [18F]FB-IL2-PET imaging did not detect a treatment-related immune response.Trial registrationClinicaltrials.gov: NCT02922283; EudraCT: 2014-003387.20 (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - June 2, 2021 Category: Nuclear Medicine Source Type: research

Biodistribution, pharmacokinetics, dosimetry of [ 68 Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [ 18 F]F-FDG PET/CT in patients with various cancers
Conclusion[68Ga]Ga-DOTA.SA.FAPi is a promising alternative among the FAPI class of molecules and performed well as compared to standard-of-care radiotracer [18F]F-FDG in the diagnosis of various cancers. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 11, 2021 Category: Nuclear Medicine Source Type: research

Predicting tumor response and outcome of second-look surgery with 18 F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer
Conclusion18F-FDG PET using EORTC or PERCIST criteria appeared to be a useful tool in ovarian cancer trials to analyze early tumor response, and predict second-look surgery outcome and survival. An advantage of PERCIST is the correlation of ΔSULpeak and ΔCA-125, PET response preceding tumor markers response by 1 month. Neither MATV nor TLG was useful in predicting survival.Trial registrationNCT01583322 ARCAGY/ GINECO GROUP GINECO-OV119, 24 April 2012 (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 11, 2021 Category: Nuclear Medicine Source Type: research

Thyroid dysfunctions induced by molecular cancer therapies: a synopsis for nuclear medicine thyroidologists
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 10, 2021 Category: Nuclear Medicine Source Type: research

Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy
AbstractPurposeVaccine-associated hypermetabolic lymphadenopathy (VAHL) is frequently observed on [18F]FDG PET-CT following BNT162b2 administration. Recent data suggest a prominent B cell germinal-center (GC) response elicited by mRNA vaccines in draining lymph nodes. Thus, in this study we aimed to explore the correlation between VAHL and humoral immunity as reflected by post-vaccination serologic testing and by comparing the incidence of VAHL between lymphoma patients treated recently with B cell depleting therapy and those that were not.MethodsA total of 137 patients with hematologic malignancy that had post-vaccination...
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 8, 2021 Category: Nuclear Medicine Source Type: research

Prognostic value of [ 18 F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies
ConclusionHigher lesional metabolic parameters are inversely related to outcome in patients undergoing ibrutinib-based therapies, and sumSUVmax emerged as a strong independent prognostic factor.Trial registrationNCT02315326;https://clinicaltrials.gov/ct2/show/NCT02315326?term=NCT02315326&draw=2&rank=1 (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 8, 2021 Category: Nuclear Medicine Source Type: research

Ultra-short time imaging of total-body PET/CT for cancer pain-induced untenable body position
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 8, 2021 Category: Nuclear Medicine Source Type: research

Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer
ConclusionsRadiogenomic data may provide clinically relevant information in NSCLC patients regarding the histotype, aggressiveness, and progression. Gene expression analysis showed potential new biomarkers and targets valuable for patient management and treatment. The application of ML allows to increase the efficacy of radiogenomic analysis and provides novel insights into cancer biology. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 7, 2021 Category: Nuclear Medicine Source Type: research

A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer
ConclusionsA PARPi-FL swish& spit solution is a rapid and non-invasive diagnostic tool that preferentially localizes fluorescent contrast to OSCC. This technique holds promise for the early detection of OSCC based on in vivo optical evaluation and targeted biopsy of suspicious lesions in the oral cavity.Trial registrationClinicaltrials.gov—NCT03085147, registered on March 21st, 2017. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 5, 2021 Category: Nuclear Medicine Source Type: research

The heterogeneity of lung perfusion patterns in SPECT/CT during COVID-19: not only embolism
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 5, 2021 Category: Nuclear Medicine Source Type: research

Authors ’ reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 4, 2021 Category: Nuclear Medicine Source Type: research

Toyama H, Li Y, Hatazawa J, Huang G, Kubota K: PET/CT for inflammatory diseases. Basic sciences, typical cases, and review
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 4, 2021 Category: Nuclear Medicine Source Type: research

Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavorable intermediate and high-risk prostate cancer
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 4, 2021 Category: Nuclear Medicine Source Type: research

Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis
ConclusionTreatment of LVV leads to reduction of arterial [18F]FDG uptake during clinical remission. [18F]FDG-PET/CT has moderate diagnostic accuracy for detecting active LVV. [18F]FDG-PET/CT may aid treatment monitoring in LVV, but its findings should be interpreted in the context of the clinical suspicion of disease activity. This study underlines the relevance of published procedural recommendations for the use of [18F]FDG-PET/CT in LVV. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 3, 2021 Category: Nuclear Medicine Source Type: research

ImmunoPET of CD38 with a radiolabeled nanobody: promising for clinical translation
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 3, 2021 Category: Nuclear Medicine Source Type: research

Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan
AbstractPurposeTo investigate the usefulness of the positron emission tomography response criteria in solid tumors 1.0 (PERCIST1.0) for predicting tumor response to neoadjuvant chemotherapy and prognosis and determine whether PERCIST improvements are necessary for esophageal squamous cell carcinoma (ESCC) patients.Patients and methodsWe analyzed the cases of 177 ESCC patients and examined the association between PERCIST and their pathological responses. Associations of whole-PERCIST with progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and Cox proportional hazards model. T...
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 2, 2021 Category: Nuclear Medicine Source Type: research

A comprehensive review of imaging findings in COVID-19 -  status in early 2021
AbstractMedical imaging methods are assuming a greater role in the workup of patients with COVID-19, mainly in relation to the primary manifestation of pulmonary disease and the tissue distribution of the angiotensin-converting-enzyme 2 (ACE 2) receptor. However, the field is so new that no consensus view has emerged guiding clinical decisions to employ imaging procedures such as radiography, computer tomography (CT), positron emission tomography (PET), and magnetic resonance imaging, and in what measure the risk of exposure of staff to possible infection could be justified by the knowledge gained. The insensitivity of cur...
Source: European Journal of Nuclear Medicine and Molecular Imaging - May 1, 2021 Category: Nuclear Medicine Source Type: research

Dosimetry and optimal scan time of [ 18 F]SiTATE-PET/CT in patients with neuroendocrine tumours
Conclusion[18F]SiTATE-PET/CT in NET shows overall high tumour-to-background ratios from 60 to 180  min after injection and an effective dose comparable to68Ga-labelled alternatives. For clinical use of [18F]SiTATE, the best compromise between image quality and tumour-to-background contrast is reached at 120  min, followed by 60 min after injection. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 29, 2021 Category: Nuclear Medicine Source Type: research

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL & gt;60 trials
ConclusionIn patients with aggressive B-cell NHL, routine BMB provides no critical staging information compared to FDG PET/CT and could therefore be omitted.Trial registrationNCT00554164 and NCT01478542 (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 29, 2021 Category: Nuclear Medicine Source Type: research

68 Ga-FAPI-46 and 18 F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 29, 2021 Category: Nuclear Medicine Source Type: research

EANM position paper on the role of radiobiology in nuclear medicine
Executive SummaryWith an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced biological responses are expected in nuclear medicine, which need to be explored. This calls for a dedicate...
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 29, 2021 Category: Nuclear Medicine Source Type: research

18 F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study
AbstractPurposeTo determine whether interim 3 ′-deoxy-3′-[18F]fluorothymidine (iFLT) PET/CT is a superior predictor of progression-free survival (PFS) compared with interim18F-fluorodeoxyglucose (iFDG) PET/CT in patients with diffuse large B cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH).MethodsNinety-two prospectively enrolled patients with DLBCL underwent both FLT-PET/CT and FDG-PET/CT 18 –24 days after two cycles of R-CHOP/R-EPOCH. Deauvil...
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 28, 2021 Category: Nuclear Medicine Source Type: research

Highlights of 33rd EANM Annual Congress 2020, virtual edition
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 28, 2021 Category: Nuclear Medicine Source Type: research

Real-time intraoperative glioma diagnosis using fluorescence imaging and deep convolutional neural networks
ConclusionOur study demonstrates that deep CNNs are better at capturing important information from fluorescence images than surgeons ’ evaluation during patient surgery. FL-CNN is highly promising to provide pathological diagnosis intraoperatively and assist neurosurgeons to obtain maximum resection safely.Trial registrationChiCTR ChiCTR2000029402. Registered 29 January 2020, retrospectively registered (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 27, 2021 Category: Nuclear Medicine Source Type: research

Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management
ConclusionsNew response criteria for NET patients undergoing PRRT will comprise multiparametric hybrid imaging and blood-based multianalyte markers. This represents tumor biology and heterogeneity. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 26, 2021 Category: Nuclear Medicine Source Type: research

Multi-scale imaging as an essential tool for precision medicine
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 22, 2021 Category: Nuclear Medicine Source Type: research

Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial
ConclusionsMPS may have prognostic value in asymptomatic diabetic patients at high cardiovascular risk over a follow-up period of 5 years. Patients with completely normal MPS have a low event rate and may not need retesting within 5  years. Patients with an abnormal MPS have higher event rates and may benefit from a combined medical and revascularization approach. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 21, 2021 Category: Nuclear Medicine Source Type: research

High-resolution radioluminescence microscopy of FDG uptake in an engineered 3D tumor-stoma model
ConclusionOur study demonstrates the feasibility of imaging the distribution of FDG uptake in engineered in vitro tumor models. With its high spatial resolution, the method can separately resolve tumor and stromal components. The approach could be extended to more advanced engineered cancer models but also to surgical tissue slices and tumor biopsies. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 21, 2021 Category: Nuclear Medicine Source Type: research

Finding our way through the labyrinth of dementia biomarkers
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 20, 2021 Category: Nuclear Medicine Source Type: research

Beyond Covid-19 vaccination-associated pitfalls on [ 18 F]Fluorodeoxyglucose (FDG) PET: a case of a concomitant sarcoidosis
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 20, 2021 Category: Nuclear Medicine Source Type: research

Correction to: High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results
A correction to this paper has been published:https://doi.org/10.1007/s00259-021-05363-7 (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 19, 2021 Category: Nuclear Medicine Source Type: research

Total-body 18 F-FDG PET/CT scan in oncology patients: how fast could it be?
AbstractPurposeThe aim of the study was to determine a faster PET acquisition protocol for a total-body PET/CT scanner by assessing the image quality that is equivalent to a conventional digital PET/CT scanner from both a phantom and a clinical perspective.MethodsA phantom study using a NEMA/IEC NU-2 body phantom was first performed in both a total-body PET/CT (uEXPLORER) and a routine digital PET/CT (uMI 780), with a hot sphere to background activity concentration ratio of 4:1. The contrast recovery coefficient (CRC), background variability (BV), and recovery coefficient (RC: RCmax and RCmean) were assessed in the uEXPLOR...
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 18, 2021 Category: Nuclear Medicine Source Type: research